Naftidrofuryl Zentiva (Naftidrofuryl Oxalate)

Naftidrofuryl Oxalate, the active ingredient in Naftidrofuryl Zentiva, is a peripheral vasodilator presented as an oral dosage form for oral use. It improves microcirculation and is employed in the management of intermittent claudication, peripheral arterial disease, and cerebrovascular insufficiency in adult patients. The drug acts by selectively antagonising 5‑HT2 receptors, leading to vasodilation of peripheral vessels and enhanced blood flow to affected limbs.

GNH USA supplies Naftidrofuryl Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naftidrofuryl Zentiva is indicated for conditions involving impaired peripheral blood flow.

- Intermittent claudication: improves walking distance by enhancing limb perfusion. - Peripheral arterial disease: reduces ischemic symptoms and supports tissue oxygenation. - Cerebrovascular insufficiency: may alleviate transient ischemic episodes by improving cerebral microcirculation.

Naftidrofuryl Zentiva may be associated with several adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset that may resolve without treatment. - Headache: transient pain often relieved with simple analgesics. - Dizziness: sensation of light‑headedness, usually temporary. - Abdominal discomfort: mild cramps or pain in the stomach area. - Flushing: brief redness of the skin, especially on the face.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting. - Allergic reactions: rash, itching, swelling, or anaphylaxis requiring immediate care. - Elevated liver enzymes: signs of hepatic stress that need laboratory monitoring. - Neutropenia: reduced white blood cell count increasing infection risk.

Before prescribing Naftidrofuryl Zentiva, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: assess kidney function and adjust therapy if necessary. - Hepatic dysfunction: monitor liver enzymes during treatment. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Elderly patients: start at the lowest effective dose and titrate cautiously. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naftidrofuryl Zentiva can interact with other medicines; awareness of major and moderate interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): combined use may cause profound hypotension. - Nitrates or other vasodilators: additive vasodilatory effect can lead to unsafe blood‑pressure drops. - Strong CYP2D6 inhibitors: may increase Naftidrofuryl plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: monitor blood pressure for excessive lowering. - Diuretics: observe electrolyte balance and renal function. - Anticoagulants: watch for increased bleeding tendency. - Alcohol: may enhance dizziness and hypotensive effects.